Get the Stockscreener App
8.125
2.02%
-0.145
Novavax Inc stock is traded at $8.125, with a volume of 1.45M.
It is down -2.02% in the last 24 hours and down -25.11% over the past month.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. Novavax works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The Company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from Europe.
See More
Previous Close:
$8.27
Open:
$8.25
24h Volume:
1.45M
Relative Volume:
0.33
Market Cap:
$1.32B
Revenue:
$847.25M
Net Income/Loss:
$-284.86M
P/E Ratio:
-3.548
EPS:
-2.29
Net Cash Flow:
$-112.35M
1W Performance:
-6.75%
1M Performance:
-25.11%
6M Performance:
-24.34%
1Y Performance:
+114.37%
1-Day Range:
$8.07
$8.37
1-Week Range:
$8.07
$8.9297
52-Week Range:
$3.60
$23.86
Novavax Inc Stock (NVAX) Company Profile
Name
Novavax Inc
Sector
Industry
Phone
240-268-2000
Address
700 QUINCE ORCHARD ROAD, GAITHERSBURG, MD
Compare NVAX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NVAX
Novavax Inc
|
8.12 | 1.32B | 847.25M | -284.86M | -112.35M | -2.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.43 | 123.91B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
715.62 | 78.94B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
651.00 | 39.98B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
274.54 | 35.89B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
118.75 | 28.75B | 3.30B | -501.07M | 1.03B | -2.1146 |
Novavax Inc Stock (NVAX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-30-24 | Downgrade | JP Morgan | Neutral → Underweight |
| May-10-24 | Upgrade | BofA Securities | Underperform → Neutral |
| May-10-24 | Upgrade | JP Morgan | Underweight → Neutral |
| Aug-09-23 | Upgrade | B. Riley Securities | Neutral → Buy |
| Apr-20-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Mar-01-23 | Downgrade | B. Riley Securities | Buy → Neutral |
| Jan-09-23 | Reiterated | B. Riley Securities | Buy |
| Dec-30-22 | Reiterated | H.C. Wainwright | Buy |
| Dec-02-22 | Initiated | Jefferies | Hold |
| Sep-22-22 | Downgrade | JP Morgan | Neutral → Underweight |
| May-20-22 | Initiated | BofA Securities | Underperform |
| Feb-23-22 | Reiterated | B. Riley Securities | Buy |
| Feb-22-22 | Resumed | Jefferies | Buy |
| Jan-21-22 | Initiated | Cowen | Outperform |
| May-12-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Dec-14-20 | Initiated | Jefferies | Buy |
| Aug-06-20 | Reiterated | H.C. Wainwright | Buy |
| Aug-05-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-20 | Downgrade | Ladenburg Thalmann | Neutral → Sell |
| Jul-16-20 | Reiterated | H.C. Wainwright | Buy |
| Jul-08-20 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-29-20 | Reiterated | B. Riley FBR | Buy |
| Jun-29-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-05-20 | Upgrade | JP Morgan | Underweight → Neutral |
| May-28-20 | Reiterated | B. Riley FBR | Buy |
| May-12-20 | Reiterated | H.C. Wainwright | Buy |
| Apr-30-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-27-19 | Resumed | B. Riley FBR | Buy |
| Aug-14-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-28-19 | Downgrade | Piper Jaffray | Overweight → Underweight |
| Dec-18-18 | Initiated | Ladenburg Thalmann | Buy |
| Dec-11-18 | Initiated | Oppenheimer | Outperform |
| Nov-26-18 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-21-18 | Upgrade | JP Morgan | Underweight → Overweight |
| Mar-29-18 | Upgrade | Seaport Global Securities | Neutral → Buy |
View All
Novavax Inc Stock (NVAX) Latest News
Novavax Inc. stock underperforms Thursday when compared to competitors - MarketWatch
BlackRock, Inc. Expands Holdings in Novavax Inc. - GuruFocus.com
Novavax Inc. stock outperforms competitors on strong trading day - MarketWatch
Novavax, Inc. (NVAX) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Novavax (NASDAQ:NVAX) Trading Down 5.7%What's Next? - MarketBeat
Zacks Research Issues Positive Forecast for Novavax Earnings - MarketBeat
Novavax Inc. stock underperforms Monday when compared to competitors - MarketWatch
Zacks Research Has Positive Estimate for Novavax Q2 Earnings - MarketBeat
This Biotech Stock Plunged 20% but Wall Street Expects a 195% Recovery - MSN
COVID-19 Vaccine Maker Novavax Trims Annual Outlook As Q2 Sales Take A Hit - MSN
Novavax Inc. stock underperforms Friday when compared to competitors - MarketWatch
(NVAX) Long Term Investment Analysis - Stock Traders Daily
New Strong Buy Stocks for January 30th - Yahoo Finance
Novavax Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Moderna stock rises following RFK Jr's comments - MSN
Nanopharmaceuticals Market Generated Opportunities, Future - openPR
Novavax, Inc. (NVAX) Stock: The Under-the-Radar Stock Poised for Massive Upside in 2025 - MSN
Moderna stock rises following RFK Jr's comments By Investing.com - Investing.com South Africa
Novavax (NASDAQ:NVAX) delivers shareholders strong 122% return over 1 year, surging 11% in the last week alone - Simply Wall St
Novavax falls after guidance cut on lower vaccine sales - MSN
Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know - Yahoo Finance
Novavax Inc. stock underperforms Monday when compared to competitors despite daily gains - MarketWatch
Novavax, Inc. (NASDAQ:NVAX) is Shah Capital Management's 2nd Largest Position - MarketBeat
Novavax (XTER:NVV1) Short-Term Capital Lease Obligation : €9.68 Mil (As of Sep. 2024) - GuruFocus.com
Novavax (XTER:NVV1) Free Cash Flow : €-112.35 Mil (TTM As of Sep. 2024) - GuruFocus.com
Novavax (NASDAQ:NVAX) Shares Up 6.1%Here's Why - MarketBeat
Trump Administration Halts All Communications From The Centers For Disease Control As Bird Flu Spreads - Benzinga
Novavax call volume above normal and directionally bullish - TipRanks
Wall Street Analysts Predict an 81.61% Upside in Novavax (NVAX): Here's What You Should Know - Yahoo Finance
Novavax, Inc. (NVAX) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
Novavax, Inc. (NASDAQ:NVAX) Receives $17.83 Average PT from Analysts - MarketBeat
10 Under-the-Radar Stocks with Massive Upside for 2025 - Insider Monkey
Novavax climbs as FDA lifts clinical hold on Covid, flu combo trials - MSN
Analysts Set Novavax, Inc. (NASDAQ:NVAX) PT at $17.83 - MarketBeat
Retail Investors Bet On Anavex Lifesciences Stock To Outperform Novavax, Rigel Pharma In Q1 On Alzheimer’s Drug Buzz - MSN
Bird Flu Raising Red Flags Among Health Officials, CDC Urges Faster Testing - Benzinga
Moderna Dropped by 20% This Week -- Is It a Smart Buy Right Now? - The Motley Fool
Novavax Cashes In On Its COVID Albatross -- Challenges Remain (Rating Upgrade) - Seeking Alpha
Novavax (NVAX) Rises But Trails Market: What Investors Should Know - Yahoo Finance
Novavax Slips 7.3% After 2024 Revenue Guidance Reaffirmed - MarketWatch
Looking Into Novavax's Recent Short Interest - Benzinga
Why Novavax (NVAX) Stock Is Falling - Benzinga
Novavax: presents its 2025 growth strategy - Marketscreener.com
Novavax Shares Strategic Updates at Healthcare Conference - TipRanks
We Asked Retail If Novavax Stock Is A Buy At Current Levels: Nearly 70% Think It's Undervalued - MSN
Novavax Inc Stock (NVAX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Novavax Inc Stock (NVAX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Kelly James Patrick | EVP, CFO and Treasurer |
Dec 31 '24 |
Option Exercise |
0.00 |
35,000 |
0 |
49,508 |
| Rodgers Richard J | Director |
Oct 29 '24 |
Option Exercise |
0.00 |
3,800 |
0 |
14,270 |
| King Rachel K. | Director |
Dec 13 '24 |
Sale |
9.02 |
4,150 |
37,435 |
14,770 |
| YOUNG JAMES F | Director |
Dec 31 '24 |
Sale |
8.00 |
5,400 |
43,200 |
51,760 |
| YOUNG JAMES F | Director |
Dec 24 '24 |
Sale |
8.48 |
4,600 |
39,008 |
57,160 |
0.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):